S&P Picks and Pans: State Street, RIM, J&J, Logitech, New York Times, Barclays
Analysts’ opinions on stocks in the news Tuesday
From Standard & Poor’sitting Equity Research
S&P MAINTAINS HOLD RECOMMENDATION ON SHARES OF STATE STREET CORP (STT; 18.80):
Fourth quarter operating EPS of $1.18, vs. $1.38, is $0.05 above our reckon. STT shares are down sharply today, reflecting a signficant increase in losses in the gathering’s investment and conduit portfolios. Its perceptible book relative length continues to decline, to roughly $10.00 in fourth quarter, vs. $15.40 in third quarter. Although its Tier-1 capital proportion is strong at 20.5%, STT’s 4.4% tangible capital levels are low, in our opinion, and and nothing else 1.05% if its conduit is consolidated. We think STT command ultimately need to raise equity. We cut our target price by $30 to $20, a below-historical 2.0 times tangible volume value. -S. Plesser
S&P DOWNGRADES OPINION ON RESEARCH IN MOTION SHARES TO HOLD FROM BUY (RIMM; 51.11):
While RIMM singly partially recaptured its late 2008 losses, shares are up 33% since November-quarter results reflecting the negative impact of a late produce launch out. RIMM’s guidance for February-quarter indicated to us that the sales pipeline is projected to be robust, but there will be gross margin pressure. While RIMM’session results to date transact not appear to have been hurt through slackened inquire for consumer electronics and the drive firmly together of workforce reductions in the key pecuniary services vertical, we see these as risks. We keep our 12-month target price of $51, based on a p-e of 14 and a p-e-growth of 0.9. -T. Rosenbluth
S&P LOWERS OPINION ON JOHNSON & JOHNSON SHARES TO BUY FROM STRONG BUY (JNJ; 57.17):
Fourth quarter operating EPS of $0.94, vs. $0.88, is $0.01 above our estimate. Revenue fell 4.9% after 3.9% forex hit. Drug sales fell 11% and medical device sales 1.9%, while consumer sales rose 1.2%. After more $0.03-$0.05 dilution from Mentor acquisition, JNJ sees 2009 EPS of $4.45-$4.55, vs. 2008’sitting $4.55. While we note JNJ’sitting lead positions in key healthcare markets, and robust R&D pipeline, we notice 2009 results impacted by means of forex, weak economies, and greater competition. We lower our target worth by $10 to $65, a peer-level p-e of 14.4 times steady our $4.50 2009 estimate, cut $0.22. Dividend yield 3.2%. -H. Saftlas
S&P LOWERS OPINION ON SHARES OF LOGITECH TO SELL FROM HOLD (LOGI; 11.35):
LOGI posts December-quarter EPS of $0.22, vs. $0.71, in the world of sense our estimate of $0.50. Revenue fell 16%, reflecting a downturn in consumer demand for PC peripherals, reluctance by retailers to hold inventory, and negative currency effects. Inventory at LOGI rose 4.9% from September-quarter, 34% from a year ago, and margins narrowed exactly. A restructuring plan is underway that is likely to cut about 550 to 600 staff. Excluding restructuring charges, we lower our EPS estimates to $0.96 from $1.35 because fiscal year 2009 (March), and to $1.00 from $1.55 for fiscal year 2010. We are reducing our 12-month target price to $10 from $17. -T. Smith-CFA
S&P MAINTAINS SELL RECOMMENDATION ON SHARES OF NEW YORK TIMES (NYT; 6.21):
NYT has entered into two private financing agreements as antidote to a total of $250 million in senior unsecured notes due 2015 with detachable warrants. Carlos Slim Helu and his subdivision of an order are the main shareholders of the companies which lent the funds and currently hold 6.9% of NYT’s Class A shares. The notes have a coupon of 14.053%, of which 3% can be paid in complaisant. The deal relieves some pressure on NYT to line up financing ahead of the May 2009 departure of a $400 the masses revolving loan agreement, but at a high cost. We cut our 2009 EPS est $0.07 to $0.46 but keep $4 target price. -L. Braverman, CFA
S&P MAINTAINS HOLD RECOMMENDATION ON ADSS OF BARCLAYS PLC (BCS; 4.29):
BCS says it knows of no justification for the 25% drop in its share price on Friday, Jan. 16, and we note that the ADSs are facing minutely this morning. We believe BCS’s comment may imply that it continues to excellence leveraged loan and similar positions on the basis that it devise ultimately receive stop to par account, the sooner than at the current distressed prices implied by marking to emporium. BCS also expects to report a pretax profit for 2008 well ahead of market according of GBP 5.3 billion; and we project GBP 6.18 billion. We maintain our income estimates and mark price. -D. Chambers
Original text: http://www.businessweek.com/investor/content/jan2009/pi20090120_487093.htm?campaign_id=rss_null
